Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk

NCT ID: NCT00192439

Last Updated: 2007-05-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-12-31

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

\- Estimate the incidence rate of hMPV infection detected by RT-PCR from frozen nasal wash aspirates in children at high risk for severe LRI disease (hospitalized at \<2 years of age).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* A prospective, epdemiological study to estimate the incidence rate of hMPV infection as determined by RT-PCR from frozen nasal wash aspirates taken from children hospitalized with LRI who are at high risk for severe disease.
* No study drug will be administered for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Respiratory Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High Risk Respiratory Disease

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be premature (less than 36 weeks gestation) and less than or equal to 12 months of age, and/or
* Be less than or equal to 24 months of age with CHD (other than uncomplicated small atrial or ventricular septal defects or patent ductus arteriosus) that is judged to be hemodynamically significant, and/or
* Be less than or equal to 24 months of age with CLD of prematurity (BPD) requiring medical intervention/management (i.e., supplemental oxygen, steroids, bronchodilators, or diuretics within the previous 6 months).
* Hospital admission diagnosis referable to an acute lower respiratory tract infection or cardio/respiratory illness with a presumed respiratory infection (e.g., bronchiolitis, bronchitis, or pneumonia or cardiac decompensation associated with respiratory infection); admission must occur between October 1 and June 30 for northern hemisphere sites, and between March 1 and November 30 for southern hemisphere sites.
* Study enrollment within 2 days after hospitalization.
* Admission from the community to the Pediatric ward, Neonatal Intensive Care Unit, or the Intensive Care Unit.
* Have written informed consent obtained from the parent or legal guardian prior to study entry.

Exclusion Criteria

* Known HIV infection or a mother with known HIV infection.
Minimum Eligible Age

1 Day

Maximum Eligible Age

24 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MedImmune LLC

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Margarita Gomez, M.D.

Role: STUDY_DIRECTOR

MedImmune LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Miller Children's Hospital

Long Beach, California, United States

Site Status

The Children's Hospital

Denver, Colorado, United States

Site Status

Children's Memorial Hospital

Chicago, Illinois, United States

Site Status

New England Medical Center

Boston, Massachusetts, United States

Site Status

The Children's Hospital

Buffalo, New York, United States

Site Status

Schneider Children's Hospital, Long Island Jewish Medical Center

New Hyde Park, New York, United States

Site Status

Univ. of Rochester Medical Center

Rochester, New York, United States

Site Status

Suny Upstate Medical Univ.

Syracuse, New York, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Wake Forest Univ. School of Medicine

Winston-Salem, North Carolina, United States

Site Status

Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

Rhode Island Hospital, Dept. of Pediatrics

Providence, Rhode Island, United States

Site Status

Lebonheur Children's Medical Center

Memphis, Tennessee, United States

Site Status

Univ. of Texas Southwestern Medical Center

Dallas, Texas, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

Children's Hospital and Regional Medical Center

Seattle, Washington, United States

Site Status

University Dept. of Paediatrics, Women's and Children's Hospital

North Adelaide, South Australia, Australia

Site Status

Royal Children's Hospital, Murdoch Children's Research Institute

Parkville, Victoria, Australia

Site Status

University of Western Australia

Perth, Western Australia, Australia

Site Status

University of Alberta

Edmonton, Alberta, Canada

Site Status

Univ. of Mannitoba

Winnipeg, Manitoba, Canada

Site Status

IWK Health Centre

Halifax, Nova Scotia, Canada

Site Status

The Hospital for Sick Children

Toronto, Ontario, Canada

Site Status

Institute of Pediatrics, University of Milan

Milan, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MI-CP096

Identifier Type: -

Identifier Source: org_study_id